^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AST-487

    i
    Other names: NVP-AST-487, AST-487, NVP-AST487, AST487
    Company:
    Novartis
    Drug class:
    RET inhibitor, FLT3 inhibitor
    Related drugs:
    2years
    AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer. (PubMed, Int J Mol Sci)
    We also identified the RET kinase pathway, targeted by AST-487, as a novel regulator of mutant hTERT promoter-driven transcription in bladder cancer cells. Collectively, our work provides new potential precision medicine approaches for cancer patients with upregulated hTERT expression, perhaps, especially those harboring mutations in both the RET gene and the hTERT promoter, such as in thyroid cancer.
    Journal
    |
    RET (Ret Proto-Oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    RET mutation • TERT mutation • RET expression
    |
    AST-487